therapeutics


Also found in: Dictionary, Thesaurus, Medical, Legal, Wikipedia.

therapeutics

the branch of medicine concerned with the treatment of disease
References in periodicals archive ?
This book is based on the same approach and intent to draw the lines of a social history of therapeutics, at the crossroads of the history of medical knowledge, medical professionalisation and doctor-patient interaction.
ExonHit Therapeutics is confident that EHT 0201 will be a positive step forward in the treatment of ALS because its development has been based on a better understanding of the molecular causes of the disease.
Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis, and related nervous system disorders.
Under the terms of the collaboration, Neuro Therapeutics intends to contribute to the collaboration all of its targets which Neuro Therapeutics believes are amenable to antibody therapeutics over a several year term that may be extended by mutual agreement.
The role of HMGB1 in acute and chronic disease is an emerging area of research and development in critical care medicine," said Frank Thomas, President and Chief Executive Officer of Critical Therapeutics.
Eric Tomlinson, President and CEO of Altea Therapeutics.
This Frost & Sullivan research service titled European Autoimmune Disease Therapeutics Market provides an overview of current treatment options, drugs in pipeline and technological advancements in the market.
Acorda Therapeutics (Nasdaq:ACOR) today announced that Ron Cohen, President and CEO, will present at the upcoming 9th Annual BIO CEO & Investor Conference on Monday, February 12th at 11:45 am Eastern Standard Time (EST).
President and CEO of Acorda Therapeutics said, "We are delighted that Ian has joined Acorda's Board.
Under its agreement with Innovative Metabolics, Critical Therapeutics is entitled to receive an initial license fee of $500,000 in cash plus a specified number of shares of preferred stock of Innovative Metabolics upon the completion of a financing by Innovative Metabolics and a one-time milestone payment of $1 million upon the achievement of all regulatory approvals.
ATLANTA -- Altea Therapeutics announces positive clinical results from Phase 1 human clinical studies for its basal insulin transdermal patch showing efficient, sustained and constant delivery of insulin at therapeutic levels.
ATLANTA -- Altea Therapeutics has entered into research agreements with two undisclosed pharmaceutical companies to examine the feasibility of developing novel transdermal patch products for two protein drugs.